BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug discovery company, announces that AstraZeneca has selected an additional novel target for idiopathic pulmonary fibrosis (IPF)...
BenevolentAI, a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through...
Singapore’s cancer population may benefit from improved access to cutting-edge clinical trials through InSite Feasibility – Oncoshot’s new digital platform that facilitates the efficient completion of oncology feasibility...
Two of ACTO’s use cases have been nominated as finalists in the eyeforpharma Awards, which focus on recognizing genuine, truly innovative and meaningful approaches to...